Rafael Holdings Inc. Class B Common Stock (RFL)
Stock · NYSE · Health Care
$1.39as of 10/16/2026
Price chart
Active signals
RFL Signal Track Record
How signals performed across all stocks →What RFL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 49 | -3.0% | 43% | September 24, 2026 |
| Bollinger Band Breakout | 25 | -4.0% | 32% | August 25, 2026 |
| Bollinger Band Breakdown | 19 | 0.0% | 47% | September 30, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +5.8% | 70% | May 26, 2026 |
| Any 20-session window (baseline) | -0.8% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RFL
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 21
- Website
- rafaelholdings.com
Fundamentals
- 1-day range
- $1.2$1.56
- Market cap
- $105.04M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.68
- Dividend yield
- —
- Beta
- 0.67
- Avg. volume
- 147.4K
How Rafael Holdings Inc. Class B Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Oct 29, 2025 · via SEC EDGAR / Finnhub
Rafael Holdings Inc. Class B Common Stock Competitors
Chosen by industry and closest market cap.
- RFLRafael Holdings Inc. Class B Common Stock$1.39▼ 5.44%Market cap $105.04MP/E —$1.12$3.96
- COYACoya Therapeutics Inc. Common Stock$4.25▼ 2.07%Market cap $107.43MP/E —$3.71$7.75
- PLYXPolaryx Therapeutics Inc. Common Stock$1.88▼ 3.59%Market cap $110.66MP/E —$1.85$48.91
- ZYBTZhengye Biotechnology Holding Limited Class A Ordinary Shares$1.4▼ 6.67%Market cap $99.05MP/E —$0.6155$8.01
- NRXPNRX Pharmaceuticals Inc. Common Stock$2.6▼ 4.06%Market cap $111.95MP/E —$1.62$5.06
- RANIRani Therapeutics Holdings Inc. Class A Common Stock$0.641▼ 5.74%Market cap $96.76MP/E —$0.462$3.87
- CUECue Biopharma Inc. Common Stock$16.71▼ 10.50%Market cap $113.45MP/E —$4.97$45.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RFL Rafael Holdings Inc. Class B Common Stock | $105.04M | — | $1.39 | ▼ 5.44% | $1.12$3.96 |
| COYA Coya Therapeutics Inc. Common Stock | $107.43M | — | $4.25 | ▼ 2.07% | $3.71$7.75 |
| PLYX Polaryx Therapeutics Inc. Common Stock | $110.66M | — | $1.88 | ▼ 3.59% | $1.85$48.91 |
| ZYBT Zhengye Biotechnology Holding Limited Class A Ordinary Shares | $99.05M | — | $1.4 | ▼ 6.67% | $0.6155$8.01 |
| NRXP NRX Pharmaceuticals Inc. Common Stock | $111.95M | — | $2.6 | ▼ 4.06% | $1.62$5.06 |
| RANI Rani Therapeutics Holdings Inc. Class A Common Stock | $96.76M | — | $0.641 | ▼ 5.74% | $0.462$3.87 |
| CUE Cue Biopharma Inc. Common Stock | $113.45M | — | $16.71 | ▼ 10.50% | $4.97$45.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Howard S. Jonas · July 29, 2026 · Grant54.9K @ $2.73
- David Polinsky · June 21, 2026 · Tax Withholding2.4K @ $2.64
- Howard S. Jonas · June 13, 2026 · Tax Withholding8.8K @ $2.33
- Howard S. Jonas · June 13, 2026 · Grant142.9K @ $1.75
Institutional Ownership
March 31, 2026
- Total shares held
- 2.39M
- Total value held
- $2.96M
- Institutional holders
- 41
- Unknown442.4K
- Unknown365.6K
- Unknown278.9K
- Unknown205.0K
- Unknown190.0K
- Unknown151.6K
- Unknown103.4K
- Unknown89.1K
- Unknown84.0K
- Unknown62.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Rafael Holdings stock drops after Phase 3 trial misses goal
Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.
Rafael Holdings stock drops after Phase 3 trial misses goal. Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.